Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ACET Relative to the S&P 500

ACET Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Adicet Bio, Inc. (NASD:ACET) seasonal charts above shows that a Buy Date of November 21 and a Sell Date of February 17 has resulted in a geometric average return of 6.11% above the benchmark rate of the S&P 500 Total Return Index over the past 7 years. This seasonal timeframe has shown positive results compared to the benchmark in 5 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 7 years by an average of 62.71% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 7 years of data is available for shares of ACET, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of off-the-shelf gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

To download ACET seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ACET